CSIMarket Company Name, Ticker, Industry, else..
 
Apyx Medical Corp  (NASDAQ: APYX)
 
Price: $3.0500 $-0.01 -0.327%
Day's High: $3.0799999237060547 Week Perf: 0.00
Day's Low: $ 3.02 30 Day Perf: -27.03 %
Volume (M): 62,100 52 Wk High: $ 5.08
Volume (M$): $ 0 52 Wk Avg: $3.63
Open: $3.06 52 Wk Low: $1.70



 Market Capitalization (Millions $) 134
 Shares Outstanding (Millions) 44
 Employees 205
 Revenues (TTM) (Millions $) 58
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 1

Business Description


Apyx Medical Corporation is a leading medical technology company that specializes in developing and commercializing innovative solutions for various surgical procedures. The company is known for its flagship product called the J-Plasma system, which utilizes a unique energy system to provide controlled and precise tissue cutting, coagulation, and ablation. Apyx Medical Corporation's technology is widely used in the fields of plastic surgery, dermatology, and other surgical specialties. The company aims to improve patient outcomes and enhance surgical precision by continuously innovating and developing advanced medical devices.


   Company Address: 5115 Ulmerton Road Clearwater 33760 FL
   Company Phone Number: 384-2323   Stock Exchange / Ticker: NASDAQ APYX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CNMD   -1.32%    
IART   -1.01%    
KIDS   -5.24%    
MDT        3.22% 
MDXG        1.56% 
SYK   -8.33%    
• View Complete Report
   



Product Service News

Apyx Medical Ramps Up Innovation in Body Contouring with New FDA Submission

Published Mon, Jan 6 2025 1:50 PM UTC

In recent weeks, Apyx Medical Corporation has made decisive strides in the aesthetic medical device sphere by submitting a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its AYON Body Contouring System. This announcement is particularly significant for the company, as it positions Apyx as a potential leader in the burgeoning body contouring ...
Business Update

Renuvion vs. Traditional Technologies A New Era in Body Contouring Surgery

Published Fri, Aug 9 2024 5:10 AM UTC

In the rapidly evolving field of cosmetic surgery, where advancements in technology can define operational success and patient outcomes, Apyx Medical Corporation has made a significant leap forward. The company recently announced the publication of a peer-reviewed clinical study, featured in the journal Plastic and Reconstructive Surgery Global Open, which compares its propr...
Business Update

Apyx Medical Corporation Reports Positive Revenue Growth and Peer-Reviewed Study on Renuvion Technology

Published Thu, Aug 8 2024 8:47 PM UTC

Apyx Medical Corporation, a Clearwater, Florida-based company specializing in innovative medical technologies, has recently announced a significant milestone in its research efforts. The company revealed the publication of a peer-reviewed article in the journal Plastic and Reconstructive Surgery - Global Open . This article details a clinical study that compared the effecti...
Contract

Apyx Medical Corporation Reports Impressive Revenue Growth in Q4 and Full Year 2023

Published Mon, Jan 8 2024 12:00 PM UTC

CLEARWATER, Fla. - Apyx Medical Corporation (NASDAQ: APYX), a leading manufacturer of proprietary helium plasma and radiofrequency technology known as Renuvion, has recently announced its preliminary revenue results for the fourth quarter and full year ended December 31, 2023. The company recorded remarkable growth in both periods, demonstrating its continued success in the ...
Stock Issue News

Empowering Innovation: Apyx Medical Secures $45 Million Credit Agreement with Perceptive Credit Holdings

Published Thu, Nov 9 2023 12:01 PM UTC



Clearwater-based Apyx Medical Corporation (NASDAQ: APYX) has recently made a significant development in securing a new five-year credit agreement with Perceptive Credit Holdings IV, LP (Perceptive), an affiliate of investment management firm Perceptive Advisors. The credit agreement is set to provide a facility of up to $45 million in senior secured term following ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.30
Price to Sales (Expected) -
Price to Book 12.06
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.95
Working Capital Ratio 5.68
Leverage Ratio (MRQ) 4.55
Total Debt to Equity 3.38
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.2 $
Revenues (TTM) 1.33 $
Cash Flow (TTM) 0.04 $
Cash 0.63 $
Book Value 0.25 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 283,439
Net Income per Employee (TTM) -41,024
Receivable Turnover Ratio (TTM) 4.14
Inventory Turnover Ratio (TTM) 2.21
Asset Turnover Ratio (TTM) 0.94

Profitability Ratios Current
Gross Margin (MRQ) 63.89 %
Operating Margin (MRQ) -13.01 %
Net Margin (MRQ) -22.13 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Apyx Medical's Segments
Surgical Aesthetics    166.52 % of total Revenue
OEM    23.44 % of total Revenue
US    126.19 % of total Revenue
Non Us    63.77 % of total Revenue

  Apyx Medical Outlook

On November 8 2024 the Apyx Medical provided following guidance

nnApyx Medical Corporation Announces Third Quarter 2024 Financial Performance; Revises 2024 Financial Projections and Unveils 2025 Financial Outlooknn

nnCLEARWATER, Fla., Nov. 8, 2024nn – nApyx Medical Corporation (NASDAQ: APYX)n, renowned for its innovative helium plasma and radiofrequency technology branded as Renuvion, has released its financial results for the third quarter ending September 30, 2024. In addition, the company has provided an update on its financial forecasts for the full year ending December 31, 2024, and has introduced preliminary expectations for the fiscal year ending December 31, 2025.

While the company has clarified its updated financial guidance, the detailed num...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.